Jan Pinkas
Hoofd Techniek/Wetenschap/O&O bij PYXIS ONCOLOGY, INC.
Profiel
Jan Pinkas is currently the Chief Scientific Officer at Pyxis Oncology, Inc. He previously worked as the VP-Translational Research & Development at ImmunoGen, Inc. and as the Senior Vice President-Translation Services at Magenta Therapeutics, Inc. Dr. Pinkas received his undergraduate degree from The Johns Hopkins University and his doctorate degree from the University of Massachusetts.
Actieve functies van Jan Pinkas
| Bedrijven | Functie | Begin |
|---|---|---|
| PYXIS ONCOLOGY, INC. | Hoofd Techniek/Wetenschap/O&O | 12-04-2022 |
Eerdere bekende functies van Jan Pinkas
| Bedrijven | Functie | Einde |
|---|---|---|
| IMMUNOGEN, INC. | Corporate Officer/Principal | - |
| MAGENTA THERAPEUTICS | Corporate Officer/Principal | - |
Opleiding van Jan Pinkas
| University of Massachusetts | Doctorate Degree |
| The Johns Hopkins University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| PYXIS ONCOLOGY, INC. | Health Technology |
| IMMUNOGEN, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |